Alterity Therapeutics to Present at the 34th Annual Roth Conference

Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on treatments for neurodegenerative diseases, announced that CEO David Stamler will present at the 34th Annual Roth Conference on March 14-15, 2022, in Dana Point, California. The company's lead asset, ATH434, targets Parkinsonian disorders, while its drug discovery platform aims to develop innovative treatments. A recorded presentation is available on the Alterity website.

MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company update and participate in investor meetings at the 34^th Annual Roth Conference.

The conference is taking place Monday, 14 March and Tuesday, 15 March 2022 in Dana Point, California, USA.

The Roth presentation recording is accessible now on the Alterity website under News.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-present-at-the-34th-annual-roth-conference-301496634.html

SOURCE Alterity Therapeutics

FAQ

When will Alterity Therapeutics present at the Roth Conference?

Alterity Therapeutics will present at the 34th Annual Roth Conference on March 14-15, 2022.

Who is the CEO of Alterity Therapeutics?

The CEO of Alterity Therapeutics is David Stamler.

What is the focus of Alterity Therapeutics?

Alterity Therapeutics focuses on developing treatments for neurodegenerative diseases.

What is the lead asset of Alterity Therapeutics?

The lead asset of Alterity Therapeutics is ATH434, which is aimed at treating Parkinsonian disorders.

Where can I find the Roth presentation recording?

The Roth presentation recording is available on the Alterity website under the News section.